Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Orexin Receptor Type 1 (Ox-1-R or Ox1R or Hypocretin Receptor Type 1 or HCRTR1) Overview 6 Therapeutics Development 7 Orexin Receptor Type 1 (Ox-1-R or Ox1R or Hypocretin Receptor Type 1 or HCRTR1) - Products under Development by Stage of Development 7 Orexin Receptor Type 1 (Ox-1-R or Ox1R or Hypocretin Receptor Type 1 or HCRTR1) - Products under Development by Therapy Area 8 Orexin Receptor Type 1 (Ox-1-R or Ox1R or Hypocretin Receptor Type 1 or HCRTR1) - Products under Development by Indication 9 Orexin Receptor Type 1 (Ox-1-R or Ox1R or Hypocretin Receptor Type 1 or HCRTR1) - Pipeline Products Glance 10 Late Stage Products 10 Early Stage Products 11 Orexin Receptor Type 1 (Ox-1-R or Ox1R or Hypocretin Receptor Type 1 or HCRTR1) - Products under Development by Companies 12 Orexin Receptor Type 1 (Ox-1-R or Ox1R or Hypocretin Receptor Type 1 or HCRTR1) - Therapeutics Assessment 14 Assessment by Monotherapy/Combination Products 14 Assessment by Mechanism of Action 15 Assessment by Route of Administration 16 Assessment by Molecule Type 17 Orexin Receptor Type 1 (Ox-1-R or Ox1R or Hypocretin Receptor Type 1 or HCRTR1) - Companies Involved in Therapeutics Development 18 C4X Discovery Holdings PLC 18 Eisai Co., Ltd. 19 Hager Biosciences, LLC 20 Heptares Therapeutics Limited 21 Merck & Co., Inc. 22 Orexin Receptor Type 1 (Ox-1-R or Ox1R or Hypocretin Receptor Type 1 or HCRTR1) - Drug Profiles 23 DORA-12 - Drug Profile 23 Product Description 23 Mechanism Of Action 23 R&D Progress 23 EORA-101 - Drug Profile 24 Product Description 24 Mechanism Of Action 24 R&D Progress 24 HTL-6641 - Drug Profile 25 Product Description 25 Mechanism Of Action 25 R&D Progress 25 lemborexant - Drug Profile 26 Product Description 26 Mechanism Of Action 26 R&D Progress 26 Small Molecule to Antagonize Orexin 1 for Central Nervous System Disorders - Drug Profile 28 Product Description 28 Mechanism Of Action 28 R&D Progress 28 Small Molecules to Antagonize CRF-R1 and OREXIN-1 for Nicotine Addiction - Drug Profile 29 Product Description 29 Mechanism Of Action 29 R&D Progress 29 Small Molecules to Antagonize Orexin-1 Receptor for Addiction - Drug Profile 30 Product Description 30 Mechanism Of Action 30 R&D Progress 30 Small Molecules to Antagonize Orexin-1 Receptor for CNS Disorders - Drug Profile 31 Product Description 31 Mechanism Of Action 31 R&D Progress 31 Orexin Receptor Type 1 (Ox-1-R or Ox1R or Hypocretin Receptor Type 1 or HCRTR1) - Dormant Projects 32 Orexin Receptor Type 1 (Ox-1-R or Ox1R or Hypocretin Receptor Type 1 or HCRTR1) - Discontinued Products 33 Orexin Receptor Type 1 (Ox-1-R or Ox1R or Hypocretin Receptor Type 1 or HCRTR1) - Featured News & Press Releases 34 May 20, 2015: Selection of drug candidate from Orexin-1 programme to treat stress-related addictive disorders and entry into pre-clinical development 34 Feb 03, 2015: Merck’s Insomnia Medicine BELSOMRA (suvorexant) C-IV, the First and Only Orexin Receptor Antagonist, Now Available in the United States 34 Dec 10, 2014: Eisai Demonstrates Efficacy Of Investigational Dual Orexin Receptor Antagonist E2006 In Sleep Initiation And Maintenance 35 Nov 26, 2014: Merck announces launch of Berusomura tablets15mg/20mg in Japan 36 Aug 13, 2014: FDA Approves BELSOMRA for the Treatment of Insomnia 36 Jul 01, 2013: Merck Receives Complete Response Letter for Suvorexant, Merck’s Investigational Medicine for Insomnia 38 May 22, 2013: Merck Wins FDA Panel Recommendation For Insomnia Drug Suvorexant At Lower Dose 39 May 20, 2013: Merck's Experimental Insomnia Drug Safe But May Carry Troublesome Side Effects, FDA Staff Says 39 Apr 03, 2013: Merck's Insomnia Drug Suvorexant Induces Sleep With Fewer Side Effects, Preclinical Study Shows 40 Nov 28, 2012: New Drug May Offer New Approach To Treating Insomnia, Study Finds 40 Nov 08, 2012: Merck Announces FDA Acceptance Of New Drug Application For Suvorexant 41 Sep 10, 2012: Merck Announces New Phase III Data For Investigational Insomnia Medicine Suvorexant 41 Jun 13, 2012: Merck Announces New Positive Data From Two Pivotal Phase III Efficacy Trials Of Suvorexant For Treatment Of Insomnia 43 Feb 06, 2012: Merck Provides Update On Development Program For Investigational Insomnia Drug, Suvorexant 45 Jun 09, 2010: Merck Announces Phase IIb Study Results Of Investigational Insomnia Therapy Drug MK-4305 45 Appendix 48 Methodology 48 Coverage 48 Secondary Research 48 Primary Research 48 Expert Panel Validation 48 Contact Us 48 Disclaimer 49

List of Tables Number of Products under Development for, H1 2016 7 Number of Products under Development by Therapy Area, H1 2016 8 Number of Products under Development by Indication, H1 2016 9 Comparative Analysis by Late Stage Development, H1 2016 10 Comparative Analysis by Early Stage Products, H1 2016 11 Number of Products under Development by Companies, H1 2016 12 Products under Development by Companies, H1 2016 13 Assessment by Monotherapy/Combination Products, H1 2016 14 Number of Products by Stage and Mechanism of Action, H1 2016 15 Number of Products by Stage and Route of Administration, H1 2016 16 Number of Products by Stage and Molecule Type, H1 2016 17 Pipeline by C4X Discovery Holdings PLC, H1 2016 18 Pipeline by Eisai Co., Ltd., H1 2016 19 Pipeline by Hager Biosciences, LLC, H1 2016 20 Pipeline by Heptares Therapeutics Limited, H1 2016 21 Pipeline by Merck & Co., Inc., H1 2016 22 Dormant Projects, H1 2016 32 Discontinued Products, H1 2016 33List of Figures Number of Products under Development for, H1 2016 7 Number of Products under Development by Top 10 Indication, H1 2016 9 Comparative Analysis by Early Stage Products, H1 2016 11 Assessment by Monotherapy/Combination Products, H1 2016 14 Number of Products by Stage and Mechanism of Actions, H1 2016 15 Number of Products by Stage and Routes of Administration, H1 2016 16 Number of Products by Stage and Molecule Type, H1 2016 17

C4X Discovery Holdings PLC Eisai Co., Ltd. Hager Biosciences, LLC Heptares Therapeutics Limited Merck & Co., Inc.